ReachMD

Episodes 1-15 of 40

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Alexander Drilon, MD

    Peer

  5

  

  RestartResume

  Keeping Pace: Advances in RET Fusion-Positive NSCLC

  0.25 credits

• • 

    

    Sara Hurvitz, MD

    Peer

  • 

    

    Jacob Sands, MD

    Peer

  6

  

  RestartResume

  Clinical Considerations for Targeted Therapies Across Multiple Tumor Types

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Helena Yu, MD

    Peer

  6

  

  RestartResume

  Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC

  0.25 credits

• • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Mikkael A. Sekeres, MD, MS

    Peer

  • 

    

    Sara M. Tinsley, PhD, ARNP, AOCNP

    Peer

  2

  

  RestartResume

  A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway

  0.50 credits

• • 

    

    Robert Mocharnuk, MD

    Peer

  • 

    

    Hossein Borghaei, DO, MS

    Peer

  1

  

  RestartResume

  Part I: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment

  0.50 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Gilberto de Lima Lopes Junior, MD, MBA, FAMS

    Peer

  4

  

  RestartResume

  Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lung Cancer

  0.25 credits

• • 

    

    William D. Tap, MD

    Peer

  • 

    

    John Healey, MD

    Peer

  5

  

  RestartResume

  Best Practices in the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

  0.25 credits

• • 

    

    William J. Gradishar MD, FASCO, FACP

    Peer

  • 

    

    Peter Schmid, FRCP, MD, PhD

    Peer

  6

  

  RestartResume

  Perspectives for Clinical Practice: The Latest Advances for HER2-positive Metastatic Breast Cancer

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Edward B. Garon, MD, MS

    Peer

  3

  

  RestartResume

  Keeping Pace: The Role of Immunotherapy After Disease Progression

  0.25 credits

• • 

    

    Ana Ferreira Castro, MD

    Peer

  • 

    

    Gilberto de Castro Junior, MD, PhD

    Peer

  • 

    

    Zujun Li, MD

    Peer

  • 

    

    Ricard Mesia, MD, PhD

    Peer

  2

  

  RestartResume

  Clinical Considerations in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  0.25 credits

• • 

    

    Mario R. Nacinovich, Jr., MSc

    Peer

  • 

    

    Bora Lim, M.D.

    Peer

  0

  

  RestartResume

  Research Highlights from ASCO: Evolving Treatment Options for Breast Cancer

• • 

    

    Jyoti D. Patel, MD, FASCO

    Peer

  • 

    

    Kai He, MD, PhD

    Peer

  • 

    

    Gilberto de Lima Lopes Junior, MD, MBA, FAMS

    Peer

  3

  

  RestartResume

  Keeping Pace with Immunotherapy Advances in Non-Small Cell Lung Cancer: Global Perspectives

  0.25 credits

• • 

    

    Warner K. Huh, MD

    Peer

  • 

    

    Deborah K. Armstrong, MD

    Peer

  • 

    

    Robert L. Coleman, MD, FACOG, FACS

    Peer

  8

  

  RestartResume

  Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Suresh S. Ramalingam, MD

    Peer

  5

  

  RestartResume

  Keeping Pace: The Role of Immunotherapy in the Frontline Setting

  0.25 credits

• • 

    

    Javier Cortes, MD, PhD

    Peer

  • 

    

    Giuseppe Curigliano, MD, PhD

    Peer

  • 

    

    Peter Schmid, FRCP, MD, PhD

    Peer

  3

  

  RestartResume

  Applying Real-World Evidence to Improve Clinical Decision-Making for Patients with HR-positive/HER2-negative Metastatic Breast Cancer

  0.25 credits

• 1
• 2
• 3
• Next